Enfortumab Vedotin OverviewEnfortumab vedotin (AGS-22M6E) is an antibody-drug conjugate designed for the treatment of cancer expressing Nectin-4. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. The most common side effects are fatigue, peripheral neuropathy (nerve damage resulting in tingling or numbness), decreased appetite, rash, alopecia (hair loss), nausea, altered taste, diarrhea, dry eye, prur...
Read more Enfortumab Vedotin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Enfortumab_vedotin
Recent Enfortumab Vedotin Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 20mg/vial, 30mg/vial
NDC Database Records for Enfortumab Vedotin: (2 results)Sorted by National Drug Code
- 51144-020 Padcev 20 mg/2.3ml Intravenous Injection, Powder, Lyophilized, for Solution by Seattle Genetics, Inc.
- 51144-030 Padcev 30 mg/3.3ml Intravenous Injection, Powder, Lyophilized, for Solution by Seattle Genetics, Inc.
Other drugs which contain Enfortumab Vedotin or a similar ingredient: (1 result)
- PADCEV Enfortumab Vedotin-ejfv